CRP and neoplasm: Specifically, the risk of tumor recurrence after TURBT for NMIBC patients in the high P-CRP group (>8.36) was 2.811 times higher than that for patients in the low P-CRP group (≤8.36) (95% CI: 0.204~0.625, P < 0.01).